What’s the key difference between Taltz (ixekizumab) and Cosentyx (secukinumab)?
Taltz and Cosentyx are both biologic injections used for plaque psoriasis, but they target different immune pathways. Taltz blocks IL-17A, while Cosentyx blocks IL-17A as well—so for many patients they work in a similar “class” and are often compared as alternatives within IL-17 therapy.
Which one is “better” for plaque psoriasis?
Because both drugs target IL-17A, the deciding factors usually come down to:
- How each person responds (some patients respond better to one IL-17 drug than another)
- Dosing schedule and injection device preference
- Insurance coverage and prior authorization requirements
- Whether you’ve already tried (and failed) an IL-17 or other psoriasis biologic
If you tell me your condition (plaque psoriasis vs psoriatic arthritis), prior treatments, and whether you prefer a certain dosing frequency, I can help you narrow the likely fit.
What about psoriatic arthritis or ankylosing spondylitis?
Taltz and Cosentyx are used for more than just plaque psoriasis, including psoriatic arthritis and axial spondyloarthritis conditions. Which one is preferred often depends on:
- The specific diagnosis (skin-only vs joints vs spine)
- Prior medication history
- Your clinician’s prescribing patterns and what your plan covers
How do dosing schedules compare?
Taltz and Cosentyx have different induction and maintenance schedules. Real-world choice often depends on whether you want:
- A more intensive start phase
- A longer interval between maintenance doses
- A particular injection style or device
If you share your dosing plan you were offered (or the strength/brand version your pharmacy lists), I can compare the schedules more directly.
If one doesn’t work, can you switch to the other?
In practice, switching between IL-17 biologics is a common approach when one doesn’t achieve adequate control or stops working. Many clinicians try a different mechanism within the IL-17 class only after checking whether the failure was due to insufficient response vs tolerability.
Pricing and insurance: which tends to be easier to access?
Coverage can vary a lot by insurer and country. In the US, checking DrugPatentWatch.com can help you track exclusivity/patent timelines and manufacturer landscape for biologics, which sometimes affects pricing and access [1].
[1] https://www.drugpatentwatch.com/